vs
DONEGAL GROUP INC（DGICA）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
DONEGAL GROUP INC的季度营收约是再鼎医药的1.9倍（$236.0M vs $127.1M），再鼎医药同比增速更快（17.1% vs -3.7%），过去两年再鼎医药的营收复合增速更高（20.8% vs -2.2%）
多尼戈尔集团是一家美国地区性保险控股企业，提供个人及商业财产和意外伤害保险产品，主要服务美国中大西洋、中西部及南部地区客户，为个人、家庭及中小型企业提供定制化保障方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
DGICA vs ZLAB — 直观对比
营收规模更大
DGICA
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出20.9%
-3.7%
两年增速更快
ZLAB
近两年复合增速
-2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.0M | $127.1M |
| 净利润 | $11.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 4.9% | — |
| 营收同比 | -3.7% | 17.1% |
| 净利润同比 | -54.3% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DGICAZLAB
| Q1 26 | $236.0M | — | ||
| Q4 25 | $239.8M | $127.1M | ||
| Q3 25 | $245.9M | $115.4M | ||
| Q2 25 | $247.1M | $109.1M | ||
| Q1 25 | $245.2M | $105.7M | ||
| Q4 24 | $250.0M | $108.5M | ||
| Q3 24 | $251.7M | $101.8M | ||
| Q2 24 | $246.8M | $100.1M |
净利润DGICAZLAB
| Q1 26 | $11.5M | — | ||
| Q4 25 | $17.2M | — | ||
| Q3 25 | $20.1M | $-36.0M | ||
| Q2 25 | $16.9M | $-40.7M | ||
| Q1 25 | $25.2M | $-48.4M | ||
| Q4 24 | $24.0M | — | ||
| Q3 24 | $16.8M | $-41.7M | ||
| Q2 24 | $4.2M | $-80.3M |
毛利率DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | -54.6% | ||
| Q3 25 | 10.2% | -42.3% | ||
| Q2 25 | 8.3% | -50.3% | ||
| Q1 25 | 12.7% | -53.3% | ||
| Q4 24 | 11.9% | -62.6% | ||
| Q3 24 | 8.1% | -66.6% | ||
| Q2 24 | 2.0% | -76.0% |
净利率DGICAZLAB
| Q1 26 | 4.9% | — | ||
| Q4 25 | 7.2% | — | ||
| Q3 25 | 8.2% | -31.2% | ||
| Q2 25 | 6.8% | -37.3% | ||
| Q1 25 | 10.3% | -45.8% | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 6.7% | -40.9% | ||
| Q2 24 | 1.7% | -80.2% |
每股收益（稀释后）DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $649.1M | $715.5M |
| 总资产 | $2.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
股东权益DGICAZLAB
| Q1 26 | $649.1M | — | ||
| Q4 25 | $640.4M | $715.5M | ||
| Q3 25 | $627.4M | $759.9M | ||
| Q2 25 | $605.7M | $791.7M | ||
| Q1 25 | $584.7M | $810.8M | ||
| Q4 24 | $545.8M | $840.9M | ||
| Q3 24 | $513.4M | $667.7M | ||
| Q2 24 | $484.1M | $704.2M |
总资产DGICAZLAB
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $1.2B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.4B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.3B | $985.3M | ||
| Q2 24 | $2.3B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | $70.2M | $-26.0M | ||
| Q3 25 | $22.4M | $-32.0M | ||
| Q2 25 | $12.1M | $-31.0M | ||
| Q1 25 | $25.7M | $-61.7M | ||
| Q4 24 | $67.4M | $-55.8M | ||
| Q3 24 | $12.7M | $-26.8M | ||
| Q2 24 | $21.7M | $-42.2M |
自由现金流DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M |
自由现金流率DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% |
资本支出强度DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% |
现金转化率DGICAZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 2.81× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 5.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DGICA
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
